Traws Pharma, Inc.

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to address critical threats to human health, primarily focusing on respiratory viral diseases. The company integrates antiviral drug development, medical intelligence, and regulatory strategy to advance its programs. Headquartered in Newtown, Pennsylvania, Traws Pharma, Inc. was formed in April 2024 through the combination of Onconova Therapeutics, Inc. and Transfynydd, with Onconova subsequently changing its name to Traws Pharma, Inc. .

The company's primary pipeline features investigational oral small-molecule antivirals. Key product candidates include Ratutrelvir (TRX01), an Mpro (3CL protease) inhibitor in development for COVID-19, designed to be ritonavir-independent, and Tivoxavir marboxil (TXM), a cap-dependent endonuclease inhibitor aimed at treating bird flu and seasonal influenza . Traws Pharma also holds legacy oncology programs, Narazaciclib and Rigosertib, for which it is actively seeking development and commercialization partners as it strategically refocuses on its antiviral portfolio .

As a publicly traded entity on NASDAQ under the ticker TRAW, Traws Pharma has been active in its development efforts and financing. In April 2026, the company secured up to $60 million in private placement financing to support its influenza program, specifically a Phase 2a human challenge trial for tivoxavir marboxil in the United Kingdom . However, in June 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) delayed this Phase 2a study, leading to a temporary setback and a planned resubmission of toxicology data in Q3 2026 . The company's leadership includes Iain D. Dukes as CEO and Dr. Robert R. Redfield, former Director of the U.S. CDC, as Chief Medical Officer .